Skip to main content
SpringerLink
Log in

Modern Treatment Concepts in Graves Disease

  • Chapter
Pediatric Ophthalmology, Neuro-Ophthalmology, Genetics

Part of the book series: Essentials in Ophthalmology ((ESSENTIALS))

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 109.00
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD 139.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info
Hardcover Book
USD 219.99
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

References

  1. Wiersinga WM, Bartalena L (2002) Epidemiology and prevention of Graves' ophthalmopathy. Thyroid 12:855–860

    Article  PubMed  Google Scholar 

  2. Gianoukakis AG, Smith TJ (2008) Recent insights into the pathogenesis and management of thyroid-associated oph-thalmopathy. Curr Opin Endocrinol Diabetes Obes 15:446–452

    Article  PubMed  CAS  Google Scholar 

  3. Feldon SE, Park DJ, O'Loughlin C W, et al (2005) Autologous T-lymphocytes stimulate proliferation of orbital fibroblasts derived from patients with Graves' ophthalmopathy. Invest Ophthalmol Vis Sci 46:3913–3921

    Article  PubMed  Google Scholar 

  4. Smith TJ (2004) Novel aspects of orbital fibroblast pathology. J Endocrinol Invest 27:246–253

    PubMed  CAS  Google Scholar 

  5. McLachlan SM, Nagayama Y, Rapoport B (2005) Insight into Graves' hyperthyroidism from animal models. Endocr Rev 26:800–832

    Article  PubMed  CAS  Google Scholar 

  6. Jacobson EM, Tomer Y (2007) The genetic basis of thyroid autoimmunity. Thyroid 17:949–961

    Article  PubMed  CAS  Google Scholar 

  7. Villadolid MC, Yokoyama N, Izumi M, et al (1995) Untreated Graves disease patients without clinical ophthal-mopathy demonstrate a high frequency of extraocular muscle (EOM) enlargement by magnetic resonance. J Clin Endocrinol Metab 80:2830–2833

    Article  PubMed  CAS  Google Scholar 

  8. Eckstein AK, Lax H, Losch C, et al (2007) Patients with severe Graves' ophthalmopathy have a higher risk of relapsing hyperthyroidism and are unlikely to remain in remission. Clin Endocrinol (Oxf) 67:607–612

    Google Scholar 

  9. Bartley GB, Fatourechi V, Kadrmas EF, et al (1996) Chronology of Graves' ophthalmopathy in an incidence cohort. Am J Ophthalmol 121:426–434

    PubMed  CAS  Google Scholar 

  10. Eckstein AK, Loesch C, Okundia H, et al (2009) Patients with euthyroid and primarily hypothyroid status have low TRAb levels and develop a tendentious milder and signifi-cantly more asymmetric Graves' Ophthalmopathy. Br J Ophthalmol in print

    Google Scholar 

  11. Khoo DH, Eng PH, Ho SC, et al (2000) Graves' ophthal-mopathy in the absence of elevated free thyroxine and triiodothyronine levels: prevalence, natural history, and thyrotropin receptor antibody levels. Thyroid 10:1093–1100

    Article  PubMed  CAS  Google Scholar 

  12. Bartley GB, Fatourechi V, Kadrmas EF, et al (1996) Clinical features of Graves' ophthalmopathy in an incidence cohort. Am J Ophthalmol 121:284–290

    PubMed  CAS  Google Scholar 

  13. Wiersinga W, Kahaly G (2007) Graves's ophthalmopathy. A multidisciplinary approach. Karger

    Google Scholar 

  14. Wiersinga WM, Perros P, Kahaly GJ, et al (2006) Clinical assessment of patients with Graves orbitopathy: the European Group on Graves Orbitopathy recommendations to generalists, specialists and clinical researchers. Eur J Endocrinol 155:387–389

    Article  PubMed  CAS  Google Scholar 

  15. Hintschich C, Haritoglou C (2005) Full thickness eyelid transsection (blepharotomy) for upper eyelid lengthening in lid retraction associated with Graves disease. Br J Ophthalmol 89:413–416

    Article  PubMed  CAS  Google Scholar 

  16. Mourits M P, Prummel MF, Wiersinga WM, et al (1997) Clinical activity score as a guide in the management of patients with Graves' ophthalmopathy. Clin Endocrinol (Oxf) 47:9–14

    Article  CAS  Google Scholar 

  17. Terwee CB, Prummel MF, Gerding MN, et al (2005) Measuring disease activity to predict therapeutic outcome in Graves' ophthalmopathy. Clin Endocrinol (Oxf) 62:145–155

    Article  CAS  Google Scholar 

  18. Mourits M P, Prummel MF, Wiersinga WM, et al (1994) Measuring eye movements in Graves ophthalmopathy. Ophthalmology 101:1341–1346

    PubMed  CAS  Google Scholar 

  19. Eckstein AK, Plicht M, Lax H, et al (2006) Thyrotropin receptor autoantibodies are independent risk factors for Graves' ophthalmopathy and help to predict severity and outcome of the disease. J Clin Endocrinol Metab 91:3464–3470

    Article  PubMed  CAS  Google Scholar 

  20. Kahaly GJ (2004) Recent developments in Graves' ophthal-mopathy imaging. J Endocrinol Invest 27:254–258

    PubMed  CAS  Google Scholar 

  21. Bartalena L, Baldeschi L, Dickinson A, et al (2008) Consensus statement of the European Group on Graves orbitopathy (EUGOGO) on management of GO. Eur J Endocrinol 158:273–285

    Article  PubMed  CAS  Google Scholar 

  22. Perros P, Crombie AL, Kendall-Taylor P (1995) Natural history of thyroid associated ophthalmopathy. Clin Endocrinol (Oxf) 42:45–50

    Article  CAS  Google Scholar 

  23. Kahaly G (2007) Management of moderately severe Graves orbitopathy. In: Wiersinga WM, Kahaly GJ (eds) Graves orbitopathy: a multidiscplinary approach. Karger, Basel, pp 120–152

    Chapter  Google Scholar 

  24. Kahaly GJ, Pitz S, Hommel G, et al (2005) Randomized, single blind trial of intravenous versus oral steroid mono-therapy in Graves orbitopathy. J Clin Endocrinol Metab 90:5234–5240

    Article  PubMed  CAS  Google Scholar 

  25. Mourits MP, van Kempen-Harteveld ML, Garcia MB, et al (2000) Radiotherapy for Graves orbitopathy: randomised placebo-controlled study. Lancet 355:1505–1509

    Article  PubMed  CAS  Google Scholar 

  26. Prummel MF, Terwee CB, Gerding MN, et al (2004) A randomized controlled trial of orbital radiotherapy versus sham irradiation in patients with mild Graves' ophthalmo-pathy. J Clin Endocrinol Metab 89:15–20

    Article  PubMed  CAS  Google Scholar 

  27. Bradley EA, Gower E W, Bradley DJ, et al (2008) Orbital radiation for graves ophthalmopathy: a report by the American academy of ophthalmology. Ophthalmology 115:398–409

    Article  PubMed  Google Scholar 

  28. Marcocci C, Bartalena L, Panicucci M, et al (1987) Orbital cobalt irradiation combined with retrobulbar or systemic corticosteroids for Graves' ophthalmopathy: a comparative study. Clin Endocrinol (Oxf) 27:33–42

    Article  CAS  Google Scholar 

  29. Marcocci C, Bartalena L, Tanda ML, et al (2001) Comparison of the eff ectiveness and tolerability of intravenous or oral glucocorticoids associated with orbital radiotherapy in the management of severe Graves' ophthalmopathy: results of a prospective, single-blind, randomized study. J Clin Endocrinol Metab 86:3562–3567

    Article  PubMed  CAS  Google Scholar 

  30. El Fassi D, Banga J P, Gilbert JA, et al (2009) Treatment of Graves disease with rituximab specifically reduces the production of thyroid stimulating autoantibodies. Clin Immunol 130:252–258

    Article  PubMed  CAS  Google Scholar 

  31. Heemstra KA, Toes RE, Sepers J, et al (2008) Rituximab in relapsing Graves disease, a phase II study. Eur J Endocrinol 159:609–615

    Article  PubMed  CAS  Google Scholar 

  32. Salvi M, Vannucchi G, Campi I, et al (2007) Treatment of Graves disease and associated ophthalmopathy with the anti-CD20 monoclonal antibody rituximab: an open study. Eur J Endocrinol 156:33–40

    Article  PubMed  CAS  Google Scholar 

  33. Paridaens D, van den Bosch WA, van der Loos TL, et al (2005) The eff ect of etanercept on Graves' ophthalmopa-thy: a pilot study. Eye 19:1286–1289

    Article  PubMed  CAS  Google Scholar 

  34. Traisk F, Tallstedt L (2001) Thyroid associated ophthalmo-pathy: botulinum toxin A in the treatment of upper eyelid retraction–a pilot study. Acta Ophthalmol Scand 79:585–588

    Article  PubMed  CAS  Google Scholar 

  35. Baldeschi L (2008) Correction of lid retraction and exophthalmos. Dev Ophthalmol 41:103–126

    Article  PubMed  Google Scholar 

  36. Garrity JA, Bahn RS (2006) Pathogenesis of graves oph-thalmopathy: implications for prediction, prevention, and treatment. Am J Ophthalmol 142:147–153

    Article  PubMed  CAS  Google Scholar 

  37. Mourits M P, Bijl HM, Baldeschi L, et al (2008) Outcome of orbital decompression for disfiguring proptosis in patients with Graves orbitopathy using various surgical procedures. Br J Ophthalmol

    Google Scholar 

  38. Esser J, Eckstein A (1999) Ocular muscle and eyelid surgery in thyroid-associated orbitopathy. Exp Clin Endocrinol Diabetes 107(Suppl 5):S214–S221

    Article  PubMed  CAS  Google Scholar 

  39. Eckstein A, Holdt M, Johnson KTM, et al (2008) Tendon elongation: a new surgical technique for large convergent squint af er three wall orbital decompression in thyroid associated ophthalmopathy. ESA proceedings

    Google Scholar 

  40. Eckstein A, Schulz S, Esser J (2004) Is combined surgical correction of horizontal and vertical squint of value in graves' ophthalmopathy? Klin Monatsbl Augenheilkd 221:769–775

    PubMed  CAS  Google Scholar 

  41. Krzizok T, Efinger K, Kaufmann H (1993) Dosierbarkeit von Augenmuskeloperationen bei endokriner Orbitopathie. Z prakt Augenheilk 14:273–279

    Google Scholar 

  42. Schittkowski M, Fichter N, Guthoff R (2004) Strabismus surgery in Graves disease–dose-eff ect relationships and functional results. Klin Monatsbl Augenheilkd 221:941–947

    Article  PubMed  CAS  Google Scholar 

  43. Neoh C, Eckstein A (2007) Eyelid surgery. In: Wiersinga WM, Kahaly GJ (eds) Graves orbitopathy: a multidisc-plinary approach. Karger, Basel, pp 188–198

    Chapter  Google Scholar 

  44. Tallstedt L, Lundell G, Torring O, et al (1992) Occurrence of ophthalmopathy af er treatment for Graves' hyperthy-roidism. The thyroid study group. N Engl J Med 326:1733–1738

    Article  CAS  Google Scholar 

  45. Marcocci C, Bruno-Bossio G, Manetti L, et al (1999) The course of Graves' ophthalmopathy is not influenced by near total thyroidectomy: a case-control study. Clin Endocrinol (Oxf) 51:503–508

    Article  CAS  Google Scholar 

  46. Dralle H, Sekulla C (2004) Morbidity af er subtotal and total thyroidectomy in patients with Graves disease: the basis for decision-making regarding surgical indication and extent of resection. Z Arztl Fortbild Qualitatssich 98(Suppl 5):45–53

    PubMed  Google Scholar 

  47. Bartalena L, Marcocci C, Bogazzi F, et al (1998) Relation between therapy for hyperthyroidism and the course of Graves' ophthalmopathy. N Engl J Med 338:73–78

    Article  PubMed  CAS  Google Scholar 

  48. Perros P, Kendall-Taylor P, Neoh C, et al (2005) A prospective study of the effects of radioiodine therapy for hyperthyroidism in patients with minimally active graves' ophthalmopathy. J Clin Endocrinol Metab 90:5321–5323

    Article  PubMed  CAS  Google Scholar 

  49. Carella C, Mazziotti G, Sorvillo F, et al (2006) Serum thy-rotropin receptor antibodies concentrations in patients with Graves disease before, at the end of methimazole treatment, and af er drug withdrawal: evidence that the activity of thyrotropin receptor antibody and/or thyroid response modify during the observation period. Thyroid 16:295–302

    Article  PubMed  CAS  Google Scholar 

  50. Schott M, Morgenthaler NG, Fritzen R, et al (2004) Levels of autoantibodies against human TSH receptor predict relapse of hyperthyroidism in Graves disease. Horm Metab Res 36:92–96

    Article  PubMed  CAS  Google Scholar 

  51. Orgiazzi J, Madec AM (2002) Reduction of the risk of relapse af er withdrawal of medical therapy for Graves disease. Thyroid 12:849–853

    Article  PubMed  CAS  Google Scholar 

  52. Khoo DH, Ho SC, Seah LL, et al (1999) The combination of absent thyroid peroxidase antibodies and high thyroid-stimulating immunoglobulin levels in Graves disease iden-tifies a group at markedly increased risk of ophthalmopathy. Thyroid 9:1175–1180

    Article  PubMed  CAS  Google Scholar 

  53. Gerding MN, van der Meer J W, Broenink M, et al (2000) Association of thyrotrophin receptor antibodies with the clinical features of Graves' ophthalmopathy. Clin Endocrinol (Oxf) 52:267–271

    Article  CAS  Google Scholar 

  54. Noh JY, Hamada N, Inoue Y, et al (2000) Thyroid-stimulating antibody is related to Graves' ophthalmopathy, but thyrotropin-binding inhibitor immunoglobulin is related to hyperthyroidism in patients with Graves disease. Thyroid 10:809–813

    Article  PubMed  CAS  Google Scholar 

  55. Eckstein AK, Plicht M, Lax H, et al (2004) Clinical results of anti-inflammatory therapy in Graves' ophthalmopa-thy and association with thyroidal autoantibodies. Clin Endocrinol (Oxf) 61:612–618

    Article  Google Scholar 

  56. Eckstein AK, Plicht M, Lax H, et al (2006) TSH-receptor autoantibodies are independent risk factors for Graves' ophthalmopathy and help to predict severity and outcome of the disease. J Clin Endocrinol Metab 91(9):3464–3470

    Article  PubMed  CAS  Google Scholar 

  57. Pfeilschifer J, Ziegler R (1996) Smoking and endocrine ophthalmopathy: impact of smoking severity and current vs lifetime cigarette consumption. Clin Endocrinol (Oxf) 45:477–481

    Article  Google Scholar 

  58. Eckstein A, Quadbeck B, Mueller G, et al (2003) Impact of smoking on the response to treatment of thyroid associated ophthalmopathy. Br J Ophthalmol 87:773–776

    Article  PubMed  CAS  Google Scholar 

  59. Cawood TJ, Moriarty P, O'Farrelly C, et al (2007) Smoking and thyroid-associated ophthalmopathy: a novel explanation of the biological link. J Clin Endocrinol Metab 92:59–64

    Article  PubMed  CAS  Google Scholar 

  60. Brix TH, Kyvik KO, Christensen K, et al (2001) Evidence for a major role of heredity in Graves disease: a population-based study of two Danish twin cohorts. J Clin Endocrinol Metab 86:930–934

    Article  PubMed  CAS  Google Scholar 

  61. Manji N, Carr-Smith JD, Boelaert K, et al (2006) Influences of age, gender, smoking, and family history on autoimmune thyroid disease phenotype. J Clin Endocrinol Metab 91:4873–4880

    Article  PubMed  CAS  Google Scholar 

  62. Ban Y, Tomer Y (2005) Genetic susceptibility in thyroid autoimmunity. Pediatr Endocrinol Rev 3:20–32

    PubMed  Google Scholar 

  63. Aust G, Krohn K, Morgenthaler NG, et al (2006) Graves disease and Hashimoto's thyroiditis in monozygotic twins: case study as well as transcriptomic and immunohistologi-cal analysis of thyroid tissues. Eur J Endocrinol 154:13–20

    Article  PubMed  CAS  Google Scholar 

  64. Eckstein A, Loesch C, Glowacka D, et al (2009) Euthyroid and primarily hypothyroid patients develop milder and significantly more asymmetric Graves ophthalmopathy. Br J Ophthalmol 93:1052–1056

    Article  PubMed  CAS  Google Scholar 

  65. Krassas GE, Gogakos A (2006) Thyroid-associated oph-thalmopathy in juvenile Graves disease–clinical, endocrine and therapeutic aspects. J Pediatr Endocrinol Metab 19:1193–1206

    Article  PubMed  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. University Eye Hospital, Hufelandstraβe 55, Essen, 45122, Germany

    Anja Eckstein

Authors
  1. Anja Eckstein
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Joachim Esser
    View author publications

    You can also search for this author in PubMed Google Scholar

Editor information

Editors and Affiliations

  1. Klinik und Poliklinik für Augenheilkunde, Justus-Liebig-University UKGM GmbH Giessen Campus, Friedrichstraße 18, Giessen, 35392, Germany

    Birgit Lorenz (Professor of Ophthalmology) (Professor of Ophthalmology)

  2. Department of Ophthalmology, Professor of Ophthalmology and Neurology Mayo Clinic, 200 First Street SW, Rochester, MN, 55905, USA

    Michael C. Brodsky

Rights and permissions

Reprints and permissions

Copyright information

© 2010 Springer-Verlag Berlin Heidelberg

About this chapter

Cite this chapter

Eckstein, A., Esser, J. (2010). Modern Treatment Concepts in Graves Disease. In: Lorenz, B., Brodsky, M.C. (eds) Pediatric Ophthalmology, Neuro-Ophthalmology, Genetics. Essentials in Ophthalmology. Springer, Berlin, Heidelberg. https://doi.org/10.1007/978-3-540-85851-5_16

Download citation

  • DOI: https://doi.org/10.1007/978-3-540-85851-5_16

  • Publisher Name: Springer, Berlin, Heidelberg

  • Print ISBN: 978-3-540-85850-8

  • Online ISBN: 978-3-540-85851-5

  • eBook Packages: MedicineMedicine (R0)

Publish with us

Policies and ethics

Search

Navigation